Ethochlorvynol en es it fr

Ethochlorvynol Brand names, Ethochlorvynol Analogs

Ethochlorvynol Brand Names Mixture

  • No information avaliable

Ethochlorvynol Chemical_Formula


Ethochlorvynol RX_link

Ethochlorvynol fda sheet

Ethochlorvynol FDA

Ethochlorvynol msds (material safety sheet)

Ethochlorvynol MSDS

Ethochlorvynol Synthesis Reference

No information avaliable

Ethochlorvynol Molecular Weight

206.028 g/mol

Ethochlorvynol Melting Point

No information avaliable

Ethochlorvynol H2O Solubility

No information avaliable

Ethochlorvynol State


Ethochlorvynol LogP


Ethochlorvynol Dosage Forms

Solution for injection (50mg/mL); Tablet (200, 400 mg)

Ethochlorvynol Indication

For the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.

Ethochlorvynol Pharmacology

Etidronate is a first generation (non-nitrogenous) bisphosphonate in the same family as clodronate and tiludronate. Etidronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the etidronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Etidronate has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia.

Ethochlorvynol Absorption

The amount of drug absorbed after an oral dose is approximately 3%.

Ethochlorvynol side effects and Toxicity

Clinical experience with acute etidronate overdosage is extremely limited. Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients. Some patients may develop vomiting. In one event, an 18-year-old female who ingested an estimated single dose of 4800 to 6000 mg (67 to 100 mg/kg) of etidronate was reported to be mildly hypocalcemic (7 .5 2 mg/ dl) and experienced paresthesia of the fingers.

Ethochlorvynol Patient Information

Ethochlorvynol Organisms Affected

Humans and other mammals